Traxanox TFA is an orally available diuretic. Traxanox TFA enhances phagocytosis of yeast granules by mouse peritoneal macrophages or rat peritoneal polymorphonuclear leukocytes in vitro. Traxanox TFA restores inhibition of antibody production in BALB/c mice. Traxanox TFA is also effective in restoring antibody production in BALB/c mice. Traxanox TFA has been shown to enhance phagocytosis in BALB/c mice.

Traxanox TFA (100 mg/kg, p.o.) showed a tendency to suppress dextran edema and cotton pellet granuloma formation in adjuvant arthritis (AA) in rats. In experimental models of delayed-type hypersensitivity (DTH), Traxanox TFA (100 mg/kg, p.o.) inhibited the accumulation of the exudate and the leucocyte migration in B. pertussis-induced pleurisy in rats. Traxanox TFA (50 mg/kg) did not show any effect on AA in Lewis rats when administered orally for 21 days after the adjuvant inoculation, but the combined administration of Traxanox TFA with hydrocortisone (10 mg/kg, p.o.) or indomethacin (0.25 mg/kg, p.o.) resulted in a synergistic inhibition of AA. When the administration of Traxanox TFA was started 21 days before the adjuvant inoculation, it inhibited AA in a dose-dependent manner (50-100 mg/kg, p.o.). On the other hand, Traxanox TFA (100 mg/kg, p.o.) enhanced the concanavalin A-induced DTH-like skin reaction in guinea pigs. These results indicate that the mode of action of Traxanox TFA on inflammatory responses resembles that of D-penicillamine or levamisole, so it may prove to be clinically effective in treating rheumatoid arthritis.[1]

DMSO: 6.25 mg/mL (15.11 mM), Sonication is recommended.